Psoriasis and Injection site erythema
Injection site erythema is found among people with Psoriasis, especially for people who are female, 50-59 old.
The study analyzes which people have Injection site erythema with Psoriasis. It is created by eHealthMe based on reports of 9,364 people who have Psoriasis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
9,364 people who have Psoriasis and Injection Site Erythema are studied.
What is Psoriasis?
Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 2,383 drugs and 1,614 conditions by eHealthMe.
What is Injection site erythema?
Injection site erythema (redness at injection site) is found to be associated with 2,131 drugs and 1,364 conditions by eHealthMe.
Number of Injection site erythema in Psoriasis reports submitted per year:
Gender of people who have Psoriasis and experienced Injection site erythema *:
Age of people who have Psoriasis and experienced Injection site erythema *:
Common co-existing conditions for these people *:
Common drugs taken by these people *:
Common symptoms for these people *:
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Injection site erythema?Check whether Injection site erythema is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Treatments, associated drugs and conditions:
- Psoriasis (412,246 reports)
- Injection site erythema (105,844 reports)
COVID vaccines that are related to Injection site erythema:
- Injection site erythema in Moderna COVID Vaccine
- Injection site erythema in Pfizer BioNTech Covid Vaccine
- Injection site erythema in Johnson and Johnson Covid Vaccine
Common drugs associated with Injection site erythema:
- Enbrel: 42,803 reports
- Humira: 15,319 reports
- Methotrexate: 6,901 reports
- Forteo: 6,006 reports
- Rebif: 4,080 reports
- Prednisone: 3,517 reports
- Dupixent: 2,407 reports
- Metformin: 1,805 reports
- Folic acid: 1,797 reports
- Copaxone: 1,708 reports
All the drugs that are associated with Injection site erythema:
- Injection site erythema (2,131 drugs)
Common conditions associated with Injection site erythema:
- Rheumatoid arthritis: 31,162 reports
- Psoriasis: 9,364 reports
- Multiple sclerosis: 7,551 reports
- Osteoporosis: 4,868 reports
- Crohn's disease: 4,176 reports
All the conditions that are associated with Injection site erythema:
- Injection site erythema (1,364 conditions)
How the study uses the data?
The study is based on Injection site erythema and Psoriasis, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Lansoprazole and Idarubicin Hydrochloride drug interaction - now
- Copegus and Skin Nodule - now
- Attention Deficit Hyperactivity Disorder and Cystitis Noninfective - now
- Peg-Intron and Oral Discomfort - 10 seconds ago
- Delstrigo and Appetite - Decreased - 11 seconds ago
- Delstrigo and Appetite Decreased - 11 seconds ago
- Duodenal Ulcer Aggravated and Colon Cancer Stage Ii - 18 seconds ago
- Bone Loss and Withdrawal Syndrome - 21 seconds ago
- Perjeta and Left Ventricular Failure - 24 seconds ago
- Amitriptyline Hydrochloride and Movement - Uncontrolled Or Slow - 30 seconds ago